Trends in schizophrenia-related mortality from 1999 to 2020: year, gender, and regional variations
Authors:
- Hurmat Fatima BhattiHBHurmat Fatima Bhatti
- Maham TahirMTMaham Tahir
- Muhammad Shaheer Bin FaheemMFMuhammad Shaheer Bin Faheem
- Momina KhabirMKMomina Khabir
- Ali TahirATAli Tahir
- Muhammad Abdullah Aftab QureshiMQMuhammad Abdullah Aftab Qureshi
- Danish Ali AshrafDADanish Ali Ashraf
- Muhammad Saad IqbalMIMuhammad Saad Iqbal
- Sumaya SamadiSSSumaya Samadi
Open Access
- 10 June 2025
- journal article
- review article
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (7) , 4336-4343
Abstract
Background: Schizophrenia affects about 1% of the global population, with 1.5 million Americans diagnosed annually. Despite higher mortality rates in this group, trends by year, gender, and region remain insufficiently explored. This study evaluated global trends in schizophrenia (F20) mortality from 1999 to 2020, analyzing variations by year, gender, and region. Additionally, we examined age-adjusted mortality rates (AAMRs) by place of death and year to provide a comprehensive understanding of these trends. Methods: The CDC WONDER database was used to analyze schizophrenia-related mortality from 1999 to 2020, calculating mortality rates and 95% confidence intervals (CIs) to assess national trends. Results: Throughout the study, males had higher AAMRs for schizophrenia (1.3%, 95% CI: 1.3–1.3) than females (0.9%, 95% Cl: 0.9–1.4). In metropolitan areas, the AAMR was 96.6, declining from 1999 to 2015 (APC: −1.07%) before rising (APC: 6.41%). Non-metropolitan areas had an AAMR of 58.9, decreasing from 1999 to 2017 (APC: −0.86%) before increasing by 2020 (APC: 8.95%). Overall, schizophrenia-related AAMRs rose from 1.2 in 1999 to 1.4 in 2020, with fluctuations. Conclusion: Schizophrenia-related mortality declined from 1999 to 2015 but rose afterward. Males consistently had higher AAMRs, while urban areas showed greater mortality, reflecting social and environmental risks. Early declines may be linked to improved psychiatric care, whereas the recent rise correlates with the opioid epidemic and COVID-19. These findings highlight the need for better investment in mental health care, early intervention, access in underserved areas, and better management of comorbidities.Keywords
This publication has 28 references indexed in Scilit:
- Increased COVID-19 mortality in patients with schizophrenia: A retrospective study in BrazilSchizophrenia Research, 2024
- Global estimates of service coverage for severe mental disorders: findings from the WHO Mental Health Atlas 2017Cambridge Prisms: Global Mental Health, 2021
- Meta-analysis of the Correlation Between Schizophrenia and Breast CancerClinical Breast Cancer, 2019
- Premature Mortality Among Adults With Schizophrenia in the United StatesJAMA Psychiatry, 2015
- The environment and susceptibility to schizophreniaProgress in Neurobiology, 2011
- Schizophrenia: A Concise Overview of Incidence, Prevalence, and MortalityEpidemiologic Reviews, 2008
- Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approachPsychological Medicine, 2006
- The Prevalence and Correlates of Nonaffective Psychosis in the National Comorbidity Survey Replication (NCS-R)Biological Psychiatry, 2005
- The Lifetime Risk of Suicide in SchizophreniaArchives of General Psychiatry, 2005
- Schizophrenia as a Complex TraitArchives of General Psychiatry, 2003